Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Share-based Compensation came in at $15.9 million in Q1 2026, down 8.82% YoY from $17.4 million in Q1 2025, and down 24.61% on a QoQ basis from $21.0 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Share-based Compensation data on file, last reported at $15.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 8.82% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.5 million (up 449.8% YoY) and the FY2025 annual result came in at $81.5 million, changed N/A from the prior year.
- Share-based Compensation slipped to $15.9 million in Q1 2026, from $21.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $652.8 million in Q1 2022 to a low of -$187.0 million in Q4 2023.
- A 5-year average of $119.4 million and a median of $38.2 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 553138.14% — and 2023, when it slumped 272.9%.
- Tracing DNA's Share-based Compensation over 5 years: stood at $108.2 million in 2022, then tumbled by 272.9% to -$187.0 million in 2023, then surged by 50.92% to -$91.8 million in 2024, then soared by 122.91% to $21.0 million in 2025, then fell by 24.61% to $15.9 million in 2026.
- The last three Share-based Compensation figures came in at $15.9 million (Q1 2026), $21.0 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.60 Mn |
| Jun 30, 2026 | 7.60 Mn |
| Mar 31, 2026 | 15.85 Mn |
| Mar 31, 2026 | 15.85 Mn |
| Dec 31, 2025 | 21.03 Mn |
| Dec 31, 2025 | 21.03 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Sep 30, 2025 | 18.10 Mn |
| Jun 30, 2025 | 22.53 Mn |
| Jun 30, 2025 | 22.53 Mn |
| Mar 31, 2025 | 17.39 Mn |
| Mar 31, 2025 | 17.39 Mn |
| Dec 31, 2024 | -91.78 Mn |
| Dec 31, 2024 | -91.78 Mn |
| Sep 30, 2024 | 14.01 Mn |
| Sep 30, 2024 | 14.01 Mn |
| Jun 30, 2024 | 38.23 Mn |
| Jun 30, 2024 | 38.23 Mn |
| Mar 31, 2024 | 40.78 Mn |
| Mar 31, 2024 | 40.78 Mn |